Skip to main content
Clinical Trials/CTRI/2024/03/063641
CTRI/2024/03/063641
Not yet recruiting
Phase 3

A clinical study to assess the effectiveness of strophanthus q in the management of coronary artery disease by elevating the ejection fraction. - Nil

il0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: I251- Atherosclerotic heart disease of native coronary artery
Sponsor
il
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
il

Eligibility Criteria

Inclusion Criteria

  • Coronary artery disease along with conventional medicines.
  • Cases that are diagnosed with reduced Ejection fraction in ECHO report.
  • Patient with less than 50% of ejection fraction.
  • Patient within the age of 25\-75 years of both sexes.

Exclusion Criteria

  • Patient with severe medical emergency condition.
  • Acute myocardial infraction.
  • Other than the coronary artery disease all cardiac disease are excluded.

Outcomes

Primary Outcomes

Not specified

Similar Trials